In business news today from SFGate, Merck and Geron announced their collaboration on research into telomerase-based cancer therapies. Telomere science, like stem cell science, is a field in which any progress lends aid to aging and serious anti-aging research - these fields all overlap in their examination of cellular mechanisms, genetics and biochemistry. So prominent private funding deals are a welcome sight - they indicate that more progress is happening out of sight, and that funding organizations believe this work to be significant. "The partners plan to try both Merck's and Geron's vaccine-making methods in cancer therapies aimed at telomerase. Each will profit from whatever version works best."